Skip Navigation


European Heart Journal Advance Access originally published online on April 11, 2005
European Heart Journal 2005 26(16):1633-1639; doi:10.1093/eurheartj/ehi222
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/16/1633    most recent
ehi222v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shai, I.
Right arrow Articles by Ma, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shai, I.
Right arrow Articles by Ma, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?

Iris Shai1,2,7,*, Eric B. Rimm1,2,3, Susan E. Hankinson2,3, Carolyn Cannuscio4, Gary Curhan3, JoAnn E. Manson2,3,5, Nader Rifai6, Meir J. Stampfer1,2,3 and Jing Ma2,3

1Department of Nutrition, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
2Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
3Channing Laboratory, Department of Medicine, Brigham Women Hospital and Harvard Medical School, Boston, MA, USA
4Merck Research Laboratories, Merck & Co. Inc., Whitehouse Station, NJ, USA
5Division of Preventive Medicine, Department of Medicine, Brigham Women Hospital and Harvard Medical School, Boston, MA, USA
6Department of Laboratory Medicine, Children's Hospital and Harvard Medical School, Boston, MA, USA
7Department of Epidemiology, S. Daniel Abraham International Center for Health and Nutrition, Ben-Gurion University, Beer-Sheva, Israel

Received 21 May 2004; revised 21 December 2004; accepted 17 February 2005; online publish-ahead-of-print 11 April 2005.

* Corresponding author. Tel: +972 8 6477449; fax: +972 8 6477638. E-mail address: ishai{at}hsph.harvard.edu

Aims With its homology with plasminogen, lipoprotein(a) [Lp(a)] may be related to thrombosis and inflammation. We assessed the role of Lp(a) in coronary heart diseases (CHD) by a recently developed assay that is not affected by the plasminogen-like Kringle-type- 2 repeats.

Methods and results Of 32 826 women from the Nurses' Health Study, who provided blood at baseline, we documented 228 CHD events during 8 years of follow-up. Each case was compared with two matched controls. In a multivariable model adjusted for body mass index, family history, hypertension, diabetes, post-menopausal hormone use, physical activity, blood drawing characteristics, and alcohol intake, the odd ratio (OR) for Lp(a) levels ≥30 mg/dL was 1.9(95% CI: 1.3–3.0) when compared with those with Lp(a)<30 mg/dL. Women with high levels of both Lp(a) (≥30 mg/dL) and fibrinogen (≥400 mg/dL) had an OR of 3.2(95% CI: 1.6–6.5) for CHD, when compared with the combination of low levels (P interaction=0.05). Women with high levels of both Lp(a) and C-reactive protein (≥3 mg/L) had an OR of 3.67(95% CI: 2.03–6.64) for CHD, when compared with the combination of low levels (P interaction=0.06).

Conclusion Lp(a) levels >30 mg/dL are associated with twice the risk of CHD events among women and may be related to thrombosis and inflammation.

Key Words: CHD • Lipoprotein(a) • Apolipoprotein(a) • Fibrinogen • C-reactive protein


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
The Emerging Risk Factors Collaboration
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA, July 22, 2009; 302(4): 412 - 423.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Suk Danik, N. Rifai, J. E. Buring, and P. M. Ridker
Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events
J. Am. Coll. Cardiol., July 8, 2008; 52(2): 124 - 131.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Anuurad, J. Rubin, A. Chiem, R. P. Tracy, T. A. Pearson, and L. Berglund
High Levels of Inflammatory Biomarkers Are Associated with Increased Allele-Specific Apolipoprotein(a) Levels in African-Americans
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1482 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. Bennet, E. Di Angelantonio, S. Erqou, G. Eiriksdottir, G. Sigurdsson, M. Woodward, A. Rumley, G. D. O. Lowe, J. Danesh, and V. Gudnason
Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease: Large-Scale Prospective Data
Arch Intern Med, March 24, 2008; 168(6): 598 - 608.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
L. Pilote, K. Dasgupta, V. Guru, K. H. Humphries, J. McGrath, C. Norris, D. Rabi, J. Tremblay, A. Alamian, T. Barnett, et al.
A comprehensive view of sex-specific issues related to cardiovascular disease
Can. Med. Assoc. J., March 13, 2007; 176(6): S1 - S44.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
E. S. Ganotakis, I. F. Gazi, J. A. Papadakis, I. A. Jagroop, D. R. Nair, and D. P. Mikhailidis
The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia
Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 35 - 42.
[Abstract] [PDF]

Home page
 JAMAHome page
J. Suk Danik, N. Rifai, J. E. Buring, and P. M Ridker
Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.
JAMA, September 20, 2006; 296(11): 1363 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Hartmann, C. von Birgelen, G. S. Mintz, M. G. Stoel, H. Eggebrecht, H. Wieneke, M. Fahy, T. Neumann, J. van der Palen, H. W. Louwerenburg, et al.
Relation Between Lipoprotein(a) and Fibrinogen and Serial Intravascular Ultrasound Plaque Progression in Left Main Coronary Arteries
J. Am. Coll. Cardiol., August 1, 2006; 48(3): 446 - 452.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.